40 mg PFS-S launched in Korea... Broadens treatment options for autoimmune diseases

Celltrion Pharm said on Nov. 2 that it had begun domestic sales of the 40 mg prefilled syringe with safety device (PFS-S) version of Yuflyma, a treatment for autoimmune diseases whose active ingredient is adalimumab, after the product was newly added to the National Health Insurance reimbursement list this month.


Celltrion Pharm's 'Yuflyma' Syringe Formulation Added to Health Insurance Coverage View original image

With this launch, Celltrion Pharm has added the safety-equipped PFS-S to its existing Yuflyma product line, which has primarily consisted of pen-type products.


A PFS is a syringe prefilled with medication, while a PFS-S is a PFS equipped with a safety device that covers the needle after injection. It is designed to reduce exposure to the needle after use, helping medical staff handle it safely.


The price of Yuflyma 40 mg PFS-S is 220,390 won per dose, the lowest among products containing the same 40 mg active ingredient that are covered by health insurance in Korea. This offers an affordable treatment option for patients requiring long-term care. Alongside the existing pen-type product, it also supports product selection based on patients' conditions, administration settings and preferences.


Following the launch of the 40 mg PFS-S, Celltrion Pharm plans to introduce Yuflyma 20 mg PFS in Korea next year. With the addition of this lower-dose product, the company will establish a domestic product lineup covering all the strengths and dosage forms available for the original medicine. It also plans to broaden the basis for prescriptions, enabling medical staff to select suitable products according to patients' conditions and required doses.



A company representative said, "For patients undergoing long-term treatment, it is important to consider not only the cost of medication but also the method of administration and handling after use when selecting a product. We will respond to the treatment needs of patients and medical staff by leveraging Yuflyma's competitive pricing and diverse product lineup."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing